The Wall ST journal reported this morning that Gilead Sciences will charge the typical patient $3,120 for the Anti- COVID drug Remdesivir.  What is striking is that Gilead will charge a higher price to US patients and a lower price to the rest of the world.  Read the entire article here:  According to the WSJ, “Remdesivir sales could reach $2.3 billion this year, of which $1.3 billion would be profit…”

Charging higher prices in the US and charging private plans more than government plans is a common practice, and one that contributes to higher rates for health insurance.  Self funded employers generally have more flexibility over design of their health plans and have some ability to design plans that avoid some of the most egregious drug pricing practices.

Are you interested in bending the curve on health care costs? Would you like a second opinion on your options? We may be able to save your firm tens or hundreds of thousands of dollars and offer a plan you can be proud of!

Click for a free consultation.